Cornerstone Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

CRANBURY, N.J., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of patients with locally advanced or metastatic pancreatic cancer. CPI-613 is the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, which is designed to disrupt the altered energy-production pathways in cancer cells.

Help employers find you! Check out all the jobs and post your resume.